Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tempest Therapeutics, Inc. TPST
$2.10
-$0.02 (-0.94%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
21493060.00000000
-
week52high
4.21
-
week52low
1.06
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-3.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:00
Описание компании
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 16 мая 2022 г. |
| William Blair | Outperform | 21 окт 2021 г. | |
| HC Wainwright & Co. | Buy | 13 июл 2021 г. | |
| Piper Sandler | Overweight | 06 июл 2021 г. | |
| Ladenburg Thalmann | Buy | 15 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brady Stephen R | A | 177300 | 177300 | 03 янв 2023 г. |
| Dubensky Thomas W. | A | 102700 | 102700 | 03 янв 2023 г. |
| Whiting Samuel | A | 69700 | 69700 | 03 янв 2023 г. |
| Trojanowski Justin | A | 20300 | 20300 | 03 янв 2023 г. |
| Maestas Nicholas | A | 38425 | 38425 | 03 янв 2023 г. |
| Trojanowski Justin | A | 2500 | 2500 | 03 окт 2022 г. |
| Maestas Nicholas | A | 51270 | 51270 | 21 июн 2022 г. |
| Lorenzo Pierre | A | 8477 | 8477 | 21 июн 2022 г. |
| Dubensky Thomas W. | A | 87801 | 87801 | 21 июн 2022 г. |
| Whiting Samuel | A | 55680 | 55680 | 21 июн 2022 г. |
Новостная лента
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
22 ноя 2022 г. в 16:05
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:30 am ET.
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
GlobeNewsWire
06 окт 2022 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company's TREX1 pipeline asset and will serve as chairperson for the “New Approaches to Solid Tumor Targeting” session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA.
Tempest to Present at the Jefferies Healthcare Conference
GlobeNewsWire
06 июн 2022 г. в 16:05
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.
3 Must Watch Penny Stocks For Your Small-Caps List
PennyStocks
27 апр 2022 г. в 17:52
These must watch penny stocks are worth giving a look The post 3 Must Watch Penny Stocks For Your Small-Caps List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Tempest Therapeutics Shares Are Rising
Benzinga
27 апр 2022 г. в 12:09
Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading higher by 29.24% at $3.05 after the company announced $15 million of private placement financing. The $15 million private investment in public equity (PIPE) financing comes from the sale of 3,149,912 shares of Tempest Therapeutics.